Catalyst Pharmaceutical CPRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's accounts receivable?
- Catalyst Pharmaceutical (CPRX) reported accounts receivable of $130.83M in Q1 2026.
- How has Catalyst Pharmaceutical's accounts receivable changed year-over-year?
- Catalyst Pharmaceutical's accounts receivable increased by 83.6% year-over-year, from $71.27M to $130.83M.
- What is the long-term trend for Catalyst Pharmaceutical's accounts receivable?
- Over 5 years (2020 to 2025), Catalyst Pharmaceutical's accounts receivable has grown at a 84.1% compound annual growth rate (CAGR), from $5.99M to $126.48M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.